Onctotarget Leads the Way in Hope for Cancer Patients

When a patient is fighting the battle against cancer, there are many factors that must be taken into consideration to determine the likelihood that they will survive beyond five years. Some of those factors are the current state of the patient’s health at the time of cancer onset, family support systems, normal type of treatment, and the type of cancer. However, just as important, or even more so, is the hope the patient has that there is a chance they will succeed. Oncotarget, a peer-reviewed journal that spans the globe, has shown direct evidence that the more hope a patient has, the more likely they are to live longer than five years with cancer.

Oncotarget focuses many of its articles and research examining the consequences the cancer management programs have on the patient’s mindset. Should these programs increase hope, they review it and recommend it to other oncologists. If these programs decrease hope, they warn other oncologists not to adopt the program. Learn more about Oncotarget at researchgate.net

Recently, Oncotarget was able to recommend the new treatment for papillary thyroid carcinoma that Dr. Carmelo Nucero developed after decades of research. Before this new treatment, papillary thyroid carcinoma posed a problem to oncologists due to its nature to become resistant to vemurafenib. The drug vemurafenib is the most common and affordable drug to treat papillary thyroid carcinoma. When a patient can no longer get vemurafenib, the patient is as good as dead.

The reason that papillary thyroid carcinoma develops a resistance to vemurafenib is that the cancer is based on a mutated BRAF gene. This mutated BRAF gene causes the immune system to attack the drug that is trying to cure it. Follow Oncotarget on Linkedin.

Dr. Carmelo Nucero was able to conduct research in this area and found there is a way to get vemurafenib to bypass the body’s immune system. When vemurafenib is administered at the same time of palbociclib, then the body stops attacking vemurafenib.

Dr. Carmelo Nucero is hopeful that since both drugs are, FDA approved treatment will be greenlighted soon. Catch the full interview on Oncotarget’s podcast now available on iTunes today.

Listen: https://soundcloud.com/oncotarget

Leave a Reply

Your email address will not be published. Required fields are marked *